Track 1: Cancer:
Genomics and Metabolomics-Cancer genomics is the investigation of the totality of DNA grouping and quality expression contrasts between tumor cells and ordinary host cells. It intends to comprehend the hereditary premise of tumor cell expansion and the development of the malignancy genome under change and determination by the body environment, the invulnerable framework and helpful mediations. The metabolites inside a cell or organic framework are being utilized to examine disease digestion system on a framework wide scale, portraying the modified pathways and their connections with each other. Malignancy metabolomics includes concoction examination by a scope of scientific stages through focused/untargeted approaches. The use of metabolomics towards growth examine has prompted to a recharged valuation for digestion system in tumor improvement and movement.
Track 2: Cancer Biomarkers:
A growth biomarker is a component or technique that shows the nearness of disease in the body. A biomarker might be any particle discharged by nearness a tumor or a particular sign of the body to the nearness of growth. Growth biomarkers are typically natural atoms found in blood, other body liquids, or tissues that are an indication of an ordinary or anomalous process, or of a condition or infection.
Track 3: Clinical Biomarkers:
Biomarkers which are utilized for clinical intentions are called clinical biomarkers. Clinical biomarkers alongside Pathological biomarkers give a lively and persuasive approach to comprehension the scope of numerous illnesses with utilizations in judgemental and explanatory the study of disease transmission, self-assertive clinical trials, screening for medications or ailment finding and anticipation. Characterized as changes in the constituents of cells or body liquids, these clinical biomarkers offer the methods for institutionalized characterization of a sickness and hazard variables, and the can broaden the base data about the hidden pathogenesis of illness.
The primary inquires about in clinical biomarkers are done in the fields of medication disclosure, oncology, pharmacogenomics and infection diagnostics. This biomarker meeting goes in insight about these fields.
Track 4: Cancer Therapy And Treatment:
Cancer can be dealt with by various procedures like Radiation Therapy; Bone Marrow Transplantation this treatment happens if there should be an occurrence of leukaemia lymphoma and myeloma. Hormone Replacement Therapy wherein the patient, over the span of restorative treatment, gets hormones, either to supplement an absence of normally happening hormones, or to substitute different hormones for actually happening hormones. Surgery and Laparoscopy portrays the execution of surgical strategies with the help of a camcorder and a few thin instruments. Immunotherapy is a kind of disease treatment that helps safe framework against battle tumor.
Track 5: Biomarkers in cancer detection:
Prognosis,or response to therapy) and the availability of appropriate assay methods. While some markers give information on the presence of cancer, others provide information on the risk of developing cancer or the likelihood of an individual responding to a particular therapy. Some examples of biomarkers used in cancer research.
Track 6: Biomarkers In Non Cancerous Diseases:
Biomarkers plan an important role in various neurological and cardiovascular diseases. The diseases which are incurable from ages are being offered a possible treatment and easy diagnosis with the help of advancements in biomarkers through different diagnostics and imaging technologies. Cardiac biomarkers and neuro biomarkers has brought a great revolution in disease diagnosis and program.
Track 7: Cell Free Biomarkers:
Circulating Biomarkers allow for the possibility of early, non-invasive detection of cancers. They also represent highly sensitive biomarkers of submissive disease and are capable of reflecting tumour affliction and cancer changing aspects. In the cancer biomarkers conferences, clinical, technical, and biological aspects of cell free biomarkers, and new technologies and techniques will be discussed. Special attention will be given to studies on clinical cases to further see the sights of the applications of these biomarkers and prospective of cell free biomarkers in disease diagnostics.
Track 8: Molecular Biomarkers Discovery:
Molecular biomarkers are molecules whose concentrations in a biological system inform about the current phenotypical state and, more importantly, may also be predictive of future phenotypic trait endpoints. The identification of biomarkers has gained much attention in targeted plant breeding since technologies have become available that measure many molecules across different levels of molecular organization and at decreasing costs .Protein biomarker discovery, Mass spectrometry based biomarker discovery, Clinical analysis of NGS samples Biomarkers for paediatric diseases, New strategies for discovery.
Track 9: Biomarkers In Screening For Cancer:
Screening for premalignant lesions or early invasive disease has the potential to reduce mortality from cancer. Because of their ease of measurement, several biomarkers have been evaluated or are currently undergoing evaluation as screening tests for early malignancy. These include the use of AFP in screening for hepatocellular cancer in high-risk subjects, CA 125 in combination with transvaginal ultrasound (TVU) in screening for epithelial ovarian cancer, PSA in screening for prostate cancer, faecal occult blood testing (FOBT) in screening for colorectal cancer (CRC) and vanillymandelic acid and homovanillic acid in screening for neuroblastoma in newborn infants, Of these biomarkers, only the use of FOBT in screening for CRC has unequivocally been shown to reduce mortality from cancer.
Track 10: Biomarkers in Breast Cancer:
Detection of breast cancer at an early stage via a biomarker assay is extremely important to reduce the burden of disease because breast cancer detected at an earlier stage is much more curable than metastatic disease. Thus, it is also necessary to identify biomarkers that may predict the occurrence of metastasis before it manifests in the patient. Based on this requirement, several potential biomarkers have gained attention and are described below: 1. the combination of three independent biomarkers, including the urokinase-dependent plasminogen activator system (uPA), the plasminogen activator inhibitor (PAI) and the Thomsen-Friedenreich (TF) antigen for an early diagnosis. 2. Mamma globin, osteopontin, snail, twist, Zeb-1, fibroblast growth factor receptors (FGFR), phosphatase and tensing homolog (PTEN) and sirtuins (SIRT) are potential biomarkers for the prediction of metastatic disease.
Track 11: Genetic biomarkers:
Cancer is a genetic disease initiated by alterations in genes, such as oncogenes and tumour suppressors that regulate cell proliferation, survival, and other homeostatic functions. Gain/ loss of gene function are predominantly responsible for oncogenic transformation. Several proto-oncogenes get converted into oncogenes with as little as a point mutation on a chromosome, thereby altering the amount of its product i.e., protein. Several non-random mutations, and translocations/ rearrangement within the regulatory region of the gene are also known to be associated with particular types of malignancy.
Track 12: Biomarkers in lung cancer:
Lung cancer is the leading cause of global cancer death in both males and females. According to the most recent projection of global mortality, by 2030 it will emerge as the third and the fifth leading cause of death in high and middle-income countries. Breath chemical tests have a broad spectrum of applications ranging from the US Food and Drug Administration-approved exhaled nitric oxide fraction (FeNO) measurement to monitor the effect of anti-inflammatory treatment in asthma, to volatile organic compound (VOC) determination and nonvolatile biomarker profiling in the cooled breath sample called exhaled breath condensate.